INTRODUCTION
Retinoic acid-inducible gene I (RIG-I) cDNA was originally identified in the RA-induced maturation model of acute myeloid leukemia (AML) and in the double-stranded RNA-induced innate immunity (Yoneyama et al., 2004; Zhang et al., 2008) . However, RIG-I as an important pattern recognition receptor, but not as a potentially critical regulator of leukemia cell proliferation and differentiation, has been well recognized (Goubau et al., 2013) . RIG-I, which features two N-terminal tandem caspase activation and recruitment domains (CARDs), a central DExH-box helicase domain, and a C-terminal domain (CTD), plays a nonredundant role in triggering innate immunity of host cells by sensing cytoplasmic viral invasion. The current model of RIG-I activity emphasizes a priming function of viral RNA on the otherwise dormant cytoplasmic RIG-I. The binding of foreign RNA ligands to RIG-I CTD and the helicase domain induces an ATP hydrolysis-dependent conformational change that exposes CARDs (Cui et al., 2008; Gee et al., 2008; O'Neill and Bowie, 2011) . The accessible CARDs on the primed RIG-I are then further activated by TRIM25 via K63-linked polyubiquitination (Gack et al., 2007; Zeng et al., 2010) , enabling the recognition by a mitochondrion membrane-anchored molecule-IPS-1 (also named MAVS/ VISA/Cardif) or cytoplasmic ASC (apoptosis-associated specklike protein containing a CARD) via homophilic CARD association (Belgnaoui et al., 2011; Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005) . This, in turn, triggers multiple signal transduction cascades that converge on the transcription activation of type I IFN, or the caspase activation of host cells (Besch et al., 2009; Fujita, 2009; Poeck et al., 2010) .
Nevertheless, a few works have also shown biological activities of RIG-I outside of sensing viral infection, such as those involving the migration and bacteria phagocytosis of immune cells (Kong et al., 2009; Mukherjee et al., 2009) . Phenotypic analysis of Rig-I À/À mice revealed that one essential function of Rig-I is to curb the scale of normal granulopoiesis in mice fed under sterile conditions (Zhang et al., 2008) . This activity was partially attributed to the ability of Rig-I to support the myeloid expression of interferon consensus sequence-binding protein (Icsbp), a classic interferon stimulatory gene (ISG) (Zhang et al., 2008) . Furthermore, a recent study indicated that RIG-I, as an ISG itself, amplifies the STAT1 activation and the induction of numerous ISGs to mediate RA-and/or IFN-mediated differentiation and growth inhibition of AML cells (Jiang et al., 2011) . Taken together, these results suggest an additional role of RIG-I in the restriction of proliferation of myeloid progenitors that are generally mobilized in response to innate or adaptive immunity-derived growth factors. However, it remains largely unknown how RIG-I is integrated into the regulatory program governing myeloid cell proliferation and differentiation whose abnormalities underpin the malignant transformation and proliferation of AML cells. (legend continued on next page)
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RIG-I Inactivates Src-AKT in Progenitor Cells of AML cells (Jiang et al., 2011) , the original refractory induction of RIG-I in RA-resistant leukemia cell lines was partially reversed when these cells started to differentiate (as indicated by CD11b upregulation) with the addition of a LSD1 inhibitor to RA treatment (Figure S1A available online) (Schenk et al., 2012) . Moreover, RIG-I upregulation in an established tetracycline-off (tet-off) RIG-I-inducible U937 AML cell model (Jiang et al., 2011) , to a level comparable to that observed in IFNa-treated U937 cells or RA-treated NB4 AML cells, resulted in significant differentiation induction, cell-cycle arrest, cell shrinkage, and cell death ( Figures 1A, S1B , and S1C). Interestingly, the majority of dying cells displayed a nonapoptosis pattern of PI and Annexin V staining ( Figure 1A , bottom panel), which could not be explained by the activation of caspases through the foreign RNA-primed RIG-I to activate the IPS-1 pathway (Besch et al., 2009) . Furthermore, compared with the combined use of RA plus RIG-I induction that effectively activated the entire caspase cascade, sole RIG-I induction only activated the initiator caspase-8, but not the initiator caspase-9 and effector caspase-3 ( Figure S1D ). Accordingly, the pretreatment with caspase inhibitors aggravated rather than lessened RIG-I-mediated U937 cell death ( Figure S1E ). These results prompted us to examine whether RIG-I induction triggers a cell death program alternative to apoptosis, such as autophagy activation (Maiuri et al., 2007; Xu et al., 2006) . Indeed, RIG-I induction resulted in autophagic vacuole accumulation within U937 cytoplasm, which was, as expected, enhanced by the administration of caspase-8 inhibitor (Figure 1B) . Additionally, other characteristic autophagic steps such as LC-3 cleavage and patch formation were also observed upon RIG-I accumulation in U937 cells (Figures S1F and S1G) , and addition of autophagy inhibitor chloroquine lessened the autophagy and cell death in parallel ( Figure S1H ), indicating that autophagy activation at least partially contributed to RIG-I upregulation-induced AML cell death.
These observations led us to evaluate whether RIG-I possesses a regulatory activity on mTOR, because the autophagy is essentially repressed by mTOR in the presence of sufficient energy supply and nutrients (Klionsky, 2007) . Besides, mTOR is critical for controlling cellular proliferation and cellular size, both of which were significantly affected by RIG-I induction (Figures S1B and S1C) Ohanna et al., 2005) . As expected, the phosphorylation levels of S6K1 (Thr 389) and 4E-BP1 (Thr 70), two representative mTOR substrates, decreased in response to RIG-I accumulation in U937 cells ( Figure S1I ). mTOR is regulated by two well-documented upstream pathways, the PI3K-AKT and the intracellular ATP/ADP ratio-AMPK axes. Because RIG-I exhibits a detectable ATPase activity that could reduce the intracellular ATP/AMP ratio (Cui et al., 2008; Gee et al., 2008) , we sought to discriminate these possibilities. Interestingly, RIG-I induction decreased the levels of p-AKT308 and p-AKT473, which signified AKT inactivation, and these events accompanied mTOR inhibition, albeit a delay in p-4E-BP1 reduction might suggest an additional regulation on 4E-BP1 ( Figure 1C ). Conversely, RIG-I knockdown (RIG-I KD) using an inducible RIG-I-specific shRNA activated both AKT and mTOR in U937 cells ( Figure 1D ) (Jiang et al., 2011) . Similarly, an aligned elevation in p-Akt308 and p-S6k1 levels was evident in the freshly isolated Rig-I À/À BM myeloid cells as compared to
Rig-I +/+ counterparts ( Figure 1E ), and this difference was greater in c-Kit + Gr-1 lo myeloid progenitors than in c-Kit
myeloid cells ( Figure 1F ). On the other hand, although ATP level decreased during the late phase of RIG-I induction in U937 cells, the reduction occurred 48 hr later than mTOR inactivation (Figures S1I and S1J) , therefore eliminating the possibility of this ATP reduction as the cause of mTOR inactivation. Accordingly, AMPK was not activated by RIG-I induction, and treating RIG-I-induced U937 cells with an AMPK inhibitor failed to fully restore mTOR activity ( Figure S1K ). Of note, the activations of IRF3 and NF-kb, which represent two core molecular events downstream of IPS-1 activation, were not detected following the sole RIG-I induction in U937 cells (Figures 1G and S1L) . Furthermore, IPS-1 knockdown (IPS-1S2) failed to restore the p-S6 (the activity indicator of S6K) or p-4E-BP1 level ( Figure 1H ), cell survival or proliferation, or immature status of RIG-I-induced U937 cells ( Figure S1M ), thus excluding the possibility that the IPS-1 pathway is integral to RIG-I-mediated mTOR inactivation.
Taken together, these results suggest that RIG-I inhibits AKTmTOR activation in myeloid progenitors and AML cells. In corroboration of this, although RA signaling in NB4 cells activated AKT-mTOR pathway during the early phase (Lal et al., 2005) , AKT-mTOR activity significantly diminished ensuing the accumulation of RIG-I during the late phase ( Figure S1N ). Likewise, RA/ IFN-induced AKT-mTOR activation in U937 cells significantly increased in the condition of RIG-I knockdown ( Figure S1O ).
Unprimed RIG-I Binds Src to Inactivate AKT-mTOR PDK1 initiates AKT activation at T308 when PI3K activity surpasses PTEN activity, while many other signaling pathways including those involving Src, PKC, MEK, or JNK potentially crosstalk with this central axis (Carracedo and Pandolfi, 2008) . By performing a pathway-screening experiment with individual kinase inhibitors, we determined that Src, in alignment with the canonical PI3K, maintained the p-AKT308 level in U937 cells (Figure 2A ). In this respect, previous works have documented that in addition to the direct or indirect stimulation of PI3K activity that activates AKT via the PIP3 generation and PDK1 corecruitment (Pleiman et al., 1994; Song et al., 2010) , Src physically associates with and tyrosine-phosphorylates AKT (Y315, Y326) to facilitate its activation by PDK1 (Chen et al., 2001; Jiang and Qiu, 2003; Lodeiro et al., 2009 ). We then examined whether RIG-I targeted Src to regulate AKT. Interestingly, the hyperactivation of AKT-mTOR in RIG-I KD U937 cells or in the freshly isolated Rig-I À/À BM cells was completely abolished by a In this regard, a recent study proposed that viral RNA-primed RIG-I and various other RIG-I partners recruit Src to a macrocomplex to fuel the strength of signal transductions that lead to the transcription activation of type I IFN (Johnsen et al., 2009 ). Nevertheless, we readily detected a RIG-I/Src association in the absence of cognate RIG-I RNA ligands both in vivo and in vitro, and actually the RNA priming partially inhibited this interaction ( Figure 2D , S2C, and S2D). Clearly, in RIG-I-induced U937 cells bearing no sign of active viral infection, coIP experiment demonstrated a physical association between RIG-I and Src (Figures 2E and 2F) . Likewise, an endogenous RIG-I/Src association was also evidenced in freshly isolated primary BM cells ( Figures 2G and 2H ). 

RIG-I Inactivates Src-AKT in Progenitor Cells
Interestingly, the total active Src (p-Src-Ya) level was not altered by Rig-I deficiency in BM cells ( Figure 2I ) or by RIG-I overexpression in U937 or Cos-7 cells ( Figures S2E and S2F ). Therefore, we hypothesized that RIG-I might inactivate AKT via affecting Src's association with AKT, or with other adaptor molecules such as c-Cbl that in turn activates PI3K to increase membrane PIP3 level (Song et al., 2010) . Notably, the Src/AKT association and AKT tyrosine phosphorylation were obviously enhanced by RIG-I knockdown, whereas the Src/c-Cbl or Src/ p85 association, p-p85, and p-PTEN levels, as well as membrane PIP3 level, were not altered under the similar conditions ( Figures 2J, 2K , and S2G). Moreover, PI3K activity and PTEN and p-PDK1 levels were not altered by RIG-I overexpression ( Figures S2H and S2I ). Taken together, these results indicate that the inhibition of Src/AKT association represents the major downstream mechanism of RIG-I regulatory effect on AKT.
RIG-I Reduction Renders SFKs Hyperactive in Activating AKT in Primary AML Blasts
Previous works have demonstrated that a constitutive hyperactivation of Akt-mTor initiates AML (Kharas et al., 2010; Yilmaz et al., 2006) , and that an abnormal activity of Src or/and other Src family kinases (SFKs) such as Lyn potentially activates AKT in AML blasts (Dos Santos et al., 2008; Gallay et al., 2009) . In this respect, we found that RIG-I also physically associated with Lyn ( Figures S3A and S3B ), although this association seemed weaker than RIG-I/Src association ( Figure S3C ). Accordingly, AKT activation in U937 RIG-I KD cells depended more on Src than on Lyn ( Figure S3D ). Therefore, we investigated whether RIG-I level among the primary human AML blasts might influence the p-AKT308 level whose elevation predicts a poor prognosis (Gallay et al., 2009) .
A survey of 46 freshly isolated BM leukemic blast samples comprising multiple subtypes of AML showed that 23 of 29 (79.3%) of p-AKT308 hi cases clustered into a putative RIG-I lo subgroup (Table S1 ; also refer to Figures 3A and S3E ). Actually, an inverse relationship was found between the graded RIG-I level and p-AKT308 level among these 46 leukemic samples (Figure 3B) . Interestingly, in line with the observation that 12 (52%) of 23 RIG-I lo /p-AKT308 hi cases were diagnosed as M3 subtype (Table S1 ), M3-specific oncogenic PML/RARa was able to decrease Rig-I mRNA level in either PML/RARa transgenic preleukemia myeloid progenitor cells or leukemia cells (Figures S3F and S3G) . As shown in Figure 3A , seven (asterisked) out of nine p-AKT308 hi /RIG-I lo AML blast samples (except P1-M5 as p-AKT308 med /RIG-I lo ) displayed normal or even moderately reduced p-Src-Ya levels. Nevertheless, 2 mM PP2 decreased (C) The in vitro inactivation of p-AKT308 by PP2 was assessed in seven AML blast samples that showed reduced RIG-I expression (see also Figure 3A ). The relative intensity ratios of p-AKT308 bands (after normalized by ACTIN) without or with PP2 treatment are shown. The band intensity without PP2 treatment is set as 1.
(D) The inactivation of AKT due to exogenous expression of RIG-I was tested in P28-M3 and P13-M0 primary AML blast samples displaying reduced RIG-I levels, and in P27-M3b AML sample with normal RIG-I level. p-AKT 308 level was monitored by intracellular staining of GFP + transduced blasts. See also Figure S3 and Table S1 .
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RIG-I Inactivates Src-AKT in Progenitor Cells p-AKT308 level in five (except P6 and P10 in the samples shown in Figure 3C ) out of seven cases examined, indicating that an insufficient RIG-I expression might have caused AKT hyperactivation through otherwise normal Src activity. In support of this, viral vector-mediated transduction of RIG-I reduced the p-AKT308 level in two RIG-I lo /p-AKT308 hi AML blast samples, but not in the P27 sample bearing a normal RIG-I level, as measured by intracellular staining (Figures 3D and S3H ).
RIG-I CARDs and PxxP Motif Collaborate to Inhibit SH3 Domain Function of Src
Next, we investigated how the RIG-I/Src association regulates the interaction between Src and AKT, which depends on the recognition of Src SH3 domain by a PxxP motif present on AKT (Boggon and Eck, 2004) . Intriguingly, at around 40 amino acids C-terminal to the RIG-I CARDs we identified a classic PxxP motif that was highly homologous to the AKT PxxP motif found in human and mice ( Figure 4A ). Small-scale coIP experiments performed with the overexpressed RIG-I and Src mutants in 293T or Cos-7 cells confirmed the involvement of RIG-I CARDs in establishing the RIG-I/Src association ( Figures S4A and S4B ) (Johnsen et al., 2009 ) and further showed that CARDs tethered with Src SH1 domain ( Figures S4A and S4B ). Nevertheless, larger-scale coIP or the in vitro binding experiment performed using purified proteins demonstrated a specific recognition of the Src SH3 domain by the RIG-I PxxP motif ( Figures 4B and  S4C ). The involvement of the Src SH1 domain in establishing the RIG-I/Src association well explained why RIG-I selectively bound to active Src ( Figures 4C and S4B ), considering that in inactive Src the SH1 domain faces inward and is inaccessible to the outside factors (Boggon and Eck, 2004) . This plausible recognition of the Src SH3 domain by the RIG-I PxxP motif promoted us to test a cooperative working model: following or simultaneous to CARDs-SH1 association, the RIG-I PxxP motif might be able to compete with the AKT PxxP motif for recognizing the Src SH3 domain ( Figure S4D ). In support of this, neither the RIG-I CARDs alone nor a PxxP motif-containing C-terminal part alone exerted a significant inhibitory effect on the Src/AKT association and AKT308 phosphorylation (Figure 4D) . Moreover, mutating PxxP (AxxA) in RIG-I, while still allowing RIG-I to bind to active Src ( Figure 4E ), disabled its ability to inhibit the Src's association with AKT ( Figure 4F ). On the other hand, disrupting ATP binding ability and ATPase activity of RIG-I through double point mutations in Walker A (K270A) and Walker B (D372A) motifs or deleting RD domain did not affect the ability of RIG-I to interfere with the Src/AKT interaction ( Figures 4G, 4H , and S4E) (Gee et al., 2008) , suggesting that Src/RIG-I association does not require a prior configuration alteration identical to that triggered by a corecognition of foreign RNA and ATP (O'Neill and Bowie, 2011). Moreover, the inducible expression of RIG-I AxxA in U937 cells, which retained the ability to activate STAT1 and increase STAT1 level ( Figure 4I ) (Jiang et al., 2011) , failed to inhibit AKT-mTOR activation and cellular growth, or to induce differentiation ( Figures 4J and 4K) , suggesting an independent functional contribution of the RIG-I PxxP motif to the regulation of the proliferation and differentiation of human AML cells via interfering the function of Src SH3 domain.
Rig-I Restricts the Proliferation of Myeloid Progenitors through Inhibiting Src-Mediated Akt-mTor Activation
As p-Akt308 level in primary myeloid progenitors was highly elevated by Rig-I deficiency ( Figure 1F ), we then examined the functional consequences of this alteration. We tested this upon the myeloid progenitors stimulated with the growth factor granulocytic and monocytic colony-stimulating factor (Gm-csf), since Gm-csf signaling involves Src family kinases (SFKs) and AKT, and its hyperactivation contributes to malignant myelopoiesis (Birnbaum et al., 2000; Horn et al., 2003; Perugini et al., 2010; Suh et al., 2005) . Besides, we previously observed that the Gm-csf stimulated myeloid cell proliferation from primary BM progenitors was significantly enhanced by Rig-I deficiency (Zhang et al., 2008) . As Rig-I selectively associated with the active Src ( Figures 4C  and 4E) , it was interesting to find that Gm-csf-stimulated Src activation increased the Rig-I/Src association in mouse myeloid cells in the condition that neither Rig-I level nor Src level was elevated ( Figure 5A ). As expected, under the Gm-csf stimulation the Src's association with Akt, Akt tyrosine phosphorylation, and Akt-mTOR activation, but not the membrane PIP3 level, was significantly enhanced by Rig-I deficiency ( Figures 5B, 5C , S5A, and S5B), and this biased Akt activation was ablated by either PP2 or the overexpression of Src DN ( Figures 5D and 5E ). The Gm-csf-stimulated myeloid colony formation from Rig-I À/À BM cells, but not from Rig-I +/+ BM cells, was significantly dampened by the inhibitors of Src, PI3K, or mTOR alike ( Figure 5F ), demonstrating an essential role of Src-Akt-mTor axis in this cytokine-stimulated myeloid cell proliferation. In accordance, the introduction of the Rig-I AxxA into Rig-I À/À BM cells failed to fully avert the abnormal proliferation of myeloid progenitors, while that of wild-type Rig-I did ( Figures  5G and 5H ).
Inhibition of In Vivo Leukemia Repopulation Depends on PxxP Motif of Rig-I
Finally we tested whether this particular regulatory activity of RIG-I on the Src SH3 domain involves the Akt activation and in vivo propagation of leukemia cells. We genetically incorporated a Dox-inducible wild-type Rig-I or Rig-I AxxA expression system into mouse PML/RARa-expressing leukemia cells (GFP after induction for 48 hr in vitro Rig-I AxxA exerted a dominantnegative effect as compared to the wild-type Rig-I that exerted an inhibitory effect on Akt activation ( Figure S6B ). Accordingly, mutating PxxP motif impaired the capacity of Rig-I to inhibit the proliferation of leukemia cells in vitro and in vivo ( Figures  6A, 6B , and S6C). Virtually, in a few cases of Rig-I group where Dox did not prevent the leukemic propagation, the majority of leukemic cells turned out to be YFP + /GFP À cells that had lost Rig-I induction by Dox, whereas the majority of repopulated leukemia cells in Rig-I AxxA group were still YFP + /GFP + (Figure S6D ). To directly test whether this Rig-I activity regulates the in vivo leukemia-repopulating capacity that indicates the leukemic stemness, after the bulk Rig-I-or Rig-I AxxA-inducible leukemic cells were treated with or without Dox in vivo for 5 days, small amounts of recovered viable leukemia cells were inoculated into the secondary recipients that received no further Dox treatment ( Figure 6C ). Of note, even over this transient induction, the overexpression of Rig-I, as compared to that of Rig-I AxxA, had relatively prompted the myeloid differentiation of total leukemic cells, as indicated by CD11b induction ( Figures 6D  and S6E ), while neither of them triggered obvious cell death ( Figure 6E ). In accord with the observed opposite effects of the Rig-I and the Rig-I AxxA on Akt-mTor activation within the leukemic cells repopulating in vivo ( Figures 6F and 6G) , the Rig-I AxxA significantly enhanced, whereas Rig-I reduced, the leukemia re-establishment of these treated leukemia cells in the secondary recipients ( Figure 6H ; see also Figure 6C ), suggesting that Rig-I potentially biases the differentiation over the 
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DISCUSSION
Mounting evidence has accumulated that RIG-I contains the specialized domains that recognize foreign RNA ligands to wake up it to initiate antiviral innate immunity (Fujita, 2009) , while this study reveals the versatility of RIG-I that, in the absence of viral infection, is able to modulate discrete signal transduction pathways controlling the proliferation and differentiation of normal or leukemic myeloid progenitors. Previous works have shown that upon activation by short foreign dsRNA, RIG-I triggers apoptosis of host cells through the activation of IPS-1 and caspases (Besch et al., 2009) , whereas this study provides evidence that RIG-I induction alone causes cell death via an apoptosis-independent pathway-AKT-mTOR inhibition and autophagy activation. In particular, RIG-I interacts with Src in a manner independent of RNA ligands, RNA priming-triggered ATPase activation, and IPS-1-IRF3 activation. However, this study does not preclude the possibility that once RIG-I is highly induced in the viral RNA-infected host or bystander cells by antiviral immunity-derived factors such as IFNs, it may inactivate AKT-mTOR and result in the restriction of viral propagation and clearance of viral entities through autophagic mechanism (Levine and Deretic, 2007) . Src and other numerous SFKs exert potent oncogenic activities in multiple forms of malignancies including AML (Dos Santos et al., 2008; Kim et al., 2009; Ozawa et al., 2008) . Of numerous proliferation regulatory signaling cascades relayed by Src, AKT-mTOR axis represents one critical pathway whose abnormalities themselves have been implicated in the leukemogenesis of AML (Kharas et al., 2010; Yilmaz et al., 2006) . Previous works have documented two possible mechanisms through which Src activates AKT-mTOR (Chen et al., 2001; Jiang and Qiu, 2003; Lodeiro et al., 2009; Pleiman et al., 1994; Song et al., 2010) . In this regard, a previous work has demonstrated that b-arrestin 2 promotes the insulin-induced AKT-mTOR activation via acting as a chaperon molecule that facilitates Src/AKT association (Luan et al., 2009 ). Here, we show a negative regulatory mechanism on this Src/AKT association, as emanated by RIG-I. Moreover, in most instances, the recognition of a substrate PxxP motif by the Src SH3 domain represents a primary mechanism to ensure the physical association of SFKs with their substrates (Boggon and Eck, 2004) , while our results suggest that this specific recognition between SH3 domain and PxxP motif is paved by a cooperative physical interaction involving the Src SH1 domain and CARDs of Rig-I. This corecognition mechanism actually orientates the regulatory effect of RIG-I onto the active but not inactive Src.
In the RA/IFN-induced differentiation model of AML cells in which RIG-I cDNA was originally identified, an initial and transient AKT-mTOR activation probably facilitates the full induction of ISG proteins (including RIG-I itself) that serve as the key effectors to RA/IFN signaling . However, a persistent AKT-mTOR activation will preclude the realization of the growth inhibition and differentiation induction (Gery et al., 2007; KannanThulasiraman et al., 2008) , or even the degradation of oncogenic protein via autophagy activation (Isakson et al., 2010) . Therefore, AKT-mTOR activation has to be limited once the accumulation of ISGs is achived. Here we provide evidence that the Srcmediated AKT activation is implicated in RA/IFN signaling, and that during the late phase of RA/IFN signaling RIG-I accumulation represents a necessary switching mechanism to dampen AKT-mTOR activation.
A frequent hyperactivation of AKT has been documented in the primary AML blasts that predict a poor prognosis (Gallay et al., 2009) . Numerous mechanisms including the activating mutations occurring to the genes encoding receptor tyrosine kinases (for example, FLT3-ITD) have been reported (Martelli et al., 2010) . A recent study emphasized a role of abnormal activation of SFK (Dos Santos et al., 2008) . Here we present an investigation of a small cohort of primary AML blast samples, indicating that RIG-I level is an independent factor negatively determining AKT activation status via regulating the SFK activity. The mechanisms responsible for RIG-I downregulation in certain types of AML blasts are not completely understood. Nevertheless, in the case of M3 subtype AML, the oncogenic fusion protein PML/RARa was able to inhibit the expression of RIG-I, probably indirectly via downregulating IRF1 (Green et al., 1999; Su et al., 2007) . Importantly, in accordance with the previous findings that AKT-mTOR supports the maintenance of leukemic stemness of AML (Kharas et al., 2010; Martelli et al., 2011; Yilmaz et al., 2006) , Rig-I activity essentially restrains the in vivo repopulating capacity of AML cells via disrupting the Src-mediated AKT-mTOR activation.
EXPERIMENTAL PROCEDURES Mice
All of the experiments using animals have followed the guideline of Shanghai Jiao-Tong University Committee for Experimental Animals. The animals were maintained with sterilized water and food.
Primary AML Blasts Samples, Cell Lines, and Reagents Human AML samples were obtained after receiving informed consents from the patients admitted to the Department of Hematology in Ruijin Hospital. Bone marrow leukemic blasts were isolated by Ficoll-Hypaque density gradient centrifugation and cultured with Isocove modified Dulbecco medium (IMDM) supplemented with 10% BIT (Stem Cell Technologies, Vancouver, Canada) for <5 days. Leukemic cell lines were cultured in RPMI-1640 medium (Invitrogen Corporation) supplemented with 10% FBS (Gibco-BRL) in 5% CO 2 and humidified atmosphere at 37 C. All-trans retinoid acid (ATRA), rapamycin, and wortmannin were purchased from Sigma-Aldrich. IFNa was obtained from R&D Systems. Doxcycline was purchased from Clontech. Tetracycline, PP2, and other kinase inhibitors were bought from Merck-Calbiochem (Darmstadt, Germany).
Colony-Forming Assay
Gm-csf-stimulated colony-forming assays were performed using the methylcellulose-based medium M3134 (Stem Cell Technologies) supplemented with 10 ng/ml recombinant mouse Gm-csf (R&D Systems).
RNA Knockdown RIG-I KD U937 cells were established by introducing the tet-off inducible siRNAs-expressing plasmids as previously described (Jiang et al., 2011) .
To knock down IPS-1 in U937/RIG-I cells, two pairs of siRNA oligonucleotides against IPS-1 were inserted into the pSilencer3.1 vector (Ambion, Austin, TX) that also contains a GFP-expressing cassette. Src and Lyn shRNAs were designed according to the online tools of Clonetech and cloned into a modified pLVX-shRNA plasmid (Clonetech, 632179) expressing YFP. These retroviral vectors were then packaged with Lenti-X 293T cells (Clonetech, 632180) for the infection of RIG-I KD U937 cells. The transduced GFP + YFP + cells were sorted with FACS. Knockdown efficiency was examined by western blotting.
Western Blotting
Total cell lysates or protein extracts were equally loaded on 8%-12% SDSpolyacrylamide gel for running and then transferred to PVDF membranes (GE Healthcare-Amersham Biosciences, UK). After blocking with 5% nonfat milk in TBST, the membranes were incubated for 2 hr or overnight with the primary antibodies. After staining with horseradish perioxidase (HRP)-linked secondary antibodies, signal detection was performed using a chemiluminescence phototope-HRP Kit (Millipore). Antibodies were purchased from Cell Signaling, Sigma-Aldrich, Santa Cruz Biotechnology, BD Pharmingen, and Millipore-Upstate. RIG-I antibodies were also prepared by Abmart Incorporation by immunizing rabbit with purified RIG-I protein. The band intensity was estimated using the Photoshop Software.
Coimmunoprecipitation Assay
The cells were lysed in lysis-buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 10% glycerol, 0.5% Triton X-100, 2 mM EDTA, 25 mM glycerophosphate, 100 mM NaF, 200 mM Na3VO4, 1 mg/ml leupeptin, 1 mg/ml aprotinin, and 1 mM PMSF). The insoluble material was removed via centrifugation, and the recovered supernatant was immunoprecipitated with antibody-coated Dynabeads (Invitrogen) according to the manufacturer's protocol. The immunoprecipitates were then washed four times with 1 ml lysis buffer and then resuspended in SDS sample buffer for western blotting analysis.
Immunofluorescence Analysis Cells were cytospun onto glass slides and fixed with 4% PFA for 30 min. After permeabilization and blocking, cells were stained sequentially with the tetramethylrhodamine isomer R (TRITC)-coupled or FITC-labeled secondary antibody (DakoCytomation, Carpinteria, CA). Cell nuclei were stained with 4 0 , 6-diamidino-2-phenylindole (DAPI). Finally, the fluorescence signals were observed using a fluorescence microscope BX61 (Olympus, Center Valley, PA).
Flow Cytometry
The nuclear DNA contents were determined by PI staining. For assessing cell survival, PI/7AAD and Annexin V stainings were measured using Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences). The flow cytometric data were collected with a BD Calibur or LSRII (Becton Dickinson) and analyzed using FlowJo or CellQuest software. In the sorting experiment, the stained cells were sorted out with a MoFlo high-speed cell sorter (DakoCytomation, Glostrup, Denmark). To perform p-AKT308 intracellular protein staining, cells were fixed with Fix Buffer (BD Biosciences), permeabilized with Perm Buffer (BD Biosciences), and then stained with a p-AKT308-PE antibody (BD Biosciences).
Leukemia Cell Inoculation and Dox Administration
Leukemic blasts derived from the hMRP8-PML/RARa-transgenic mice were first infected with MigR1-TET3G-IRES-YFP retroviral vector during a shortterm in vitro culture and were then transplanted into syngeneic mice to allow the transduced leukemia cells to repopulate in vivo. Next, the freshly isolated YFP + leukemic bone marrow blasts were infected with a Dox-inducible Rig-I or Rig-I AxxA retroviral vector coexpressing GFP and inoculated into syngeneic recipients to establish YFP + /GFP + leukemia that were responsive to doxcycline (Dox).
Secondary Transplantation
Once the repopulation of leukemia cells was detected in the peripheral blood, drinking water with or without 200 mg/ml Dox was given for 5 days. Subsequently, 200 or 1,000 freshly isolated viable GFP + YFP + bone marrow leukemia cells were injected intravenously into the secondary recipients, and the reestablishment of leukemia was monitored up to 80 days. 
